Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain; Centro de Salud Pública de Castellón, Castellón, Spain.
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.
Vaccine. 2017 Dec 19;35(52):7331-7338. doi: 10.1016/j.vaccine.2017.10.100. Epub 2017 Nov 8.
The 2015/2016 influenza season was characterized in Europe by the circulation of A(H1N1)pdm09 clade 6B.1 and B/Victoria-lineage influenza viruses. The components of the vaccines used in the current and past two seasons in the Valencia region were similar but not well matched to the 2015/2016 dominant influenza-circulating strains. We estimate influenza vaccine effectiveness (IVE) and interference of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-lineage in this particular season.
The Valencia Hospital Network for the Study of Influenza runs an active surveillance hospital-based study to collect clinical and virological data from consecutive admissions possibly related to influenza. Combined nasopharyngeal and pharyngeal swabs are analyzed by reverse transcription polymerase chain reaction, and the hemagglutinin is sequenced in a sample of positive influenza specimens. Vaccination is ascertained consulting a population vaccine information system. We estimate IVE using a test-negative approach.
During the 2015-2016 season, we recruited 1049 eligible admissions of patients 60 years or older, and 187 tested positive for influenza. The adjusted IVE in preventing admission with A(H1N1)pdm09 was 20.2%; 95% confidence interval (CI) -21.3-47.5% and -33.2%; 95% CI, -140.1-26.1% in preventing admission with B/Victoria-lineage. The majority of A(H1N1)pdm09 sequenced viruses belonged to the emerging 6B.1 subclade, defined by S162N and I216T mutations in the hemagglutinin protein. When we restricted our analysis to those not vaccinated in the previous year, unadjusted IVE was 84.9% (95% CI 9.9-100.0) overall, 77.9% (-32.7-100.0%) in preventing A(H1N1)pdm09 and 48.8% (-219.5-100.0%) in preventing B/Yamagata-lineage admission.
Our findings indicate that IVE was low in preventing A(H1N1)pdm09 and strongly correlated with vaccination in the previous season. No effect in preventing admission with B/Victoria-lineage was observed. For the 2015/2016 season, IVE was low due to a mismatch and lack of concordance between the circulating and vaccine viruses.
2015/2016 年流感季节,欧洲流行 A(H1N1)pdm09 分支 6B.1 和 B/Victoria 谱系流感病毒。巴伦西亚地区当前和过去两个季节使用的疫苗成分相似,但与 2015/2016 年主要流行的流感病毒株不完全匹配。我们估计了本季甲型 H1N1pdm09 或 B/Victoria 谱系流感疫苗的有效性(IVE)和先前接种对预防入院的干扰。
巴伦西亚流感网络医院进行了一项基于医院的主动监测研究,从可能与流感相关的连续住院患者中收集临床和病毒学数据。将鼻咽和咽拭子联合进行逆转录聚合酶链反应分析,并对阳性流感标本中的血凝素进行测序。通过人群疫苗信息系统确定接种情况。我们使用阴性检测方法估计 IVE。
在 2015-2016 年期间,我们招募了 1049 名 60 岁及以上符合条件的住院患者,其中 187 例检测出流感阳性。预防 A(H1N1)pdm09 入院的调整后 IVE 为 20.2%;95%置信区间(CI)-21.3-47.5%和-33.2%;95%CI,-140.1-26.1%,预防 B/Victoria 谱系入院。测序的甲型 H1N1pdm09 病毒大多数属于新兴的 6B.1 亚分支,其特征是血凝素蛋白中的 S162N 和 I216T 突变。当我们将分析限制在去年未接种疫苗的人群中时,总体未调整的 IVE 为 84.9%(95%CI 9.9-100.0),预防 A(H1N1)pdm09 的为 77.9%(-32.7-100.0%),预防 B/Yamagata 谱系入院的为 48.8%(-219.5-100.0%)。
我们的研究结果表明,预防 A(H1N1)pdm09 的 IVE 较低,与上一季的疫苗接种密切相关。预防 B/Victoria 谱系入院的效果不明显。2015/2016 年,由于循环病毒和疫苗病毒之间的不匹配和不一致,IVE 较低。